News & Events
Seres Therapeutics to Present at the Jefferies 2019 Healthcare Conference (opens in a new tab)
Microbiota Restoration Takes the Podium at DDW 2019: Investigational Microbiota-Based Therapies for Recurrent C. diff Highlighted (opens in a new tab)
Vedanta Biosciences Closes Extended $45.5 Million Series C Financing (opens in a new tab)
Vedanta Biosciences Key Microbiome Patent Upheld in European Opposition Proceedings (opens in a new tab)
Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update (opens in a new tab)
Seres Therapeutics to Host First Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on May 2, 2019 (opens in a new tab)
Seres Therapeutics Presents New Preclinical Data Supporting the Development of SER-401 for Immuno-Oncology at the 2019 American Association for Cancer Research Annual Meeting (opens in a new tab)
Microbiome Health Index™ Platform to be Presented at Gut Microbiota for Health Summit 2019 (opens in a new tab)
MTIG Position Statement for FMT (opens in a new tab)
Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca (opens in a new tab)
Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates (opens in a new tab)
Seres Therapeutics to Present at Three Upcoming March Conferences (opens in a new tab)
Vedanta Biosciences Publishes Seminal Research in Leading Scientific Journal for its Immuno-oncology Candidate, VE800 (opens in a new tab)
PureTech’s Vedanta Biosciences Publishes Seminal Research in Leading Scientific Journal for its Immuno-oncology Candidate, VE800 (opens in a new tab)
Vedanta Biosciences Raises $27 Million Series C Financing to Advance Clinical Pipeline of Microbiome-Derived Product Candidates (opens in a new tab)
Vedanta Biosciences Initiates Phase 2 Study for Lead Rationally-Defined Bacterial Consortium Product Candidate, VE303 (opens in a new tab)
Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers (opens in a new tab)
Vedanta Biosciences Announces Initiation of Phase 1 Clinical Study with Janssen of Microbiome-Derived Product Candidate for Inflammatory Bowel Disease (opens in a new tab)
Pioneer of the Year award – Silvia Caballero! (opens in a new tab)
Vedanta Biosciences Announces Preclinical Data on Microbiome-Derived Immuno-Oncology Candidate (opens in a new tab)